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Abstract     
A catalytic diastereoselective Mannich reaction promoted by chiral bifunctional urea-type 
organocatalysts has been developed. Treatment of N-Boc-3-ketoproline with N-Boc-aldimines 
under mild conditions afforded the corresponding unnatural proline based amino acid derivatives 
with excellent diastereoselectivities (up to 99:1) and enantioselectivities (up to 97% ee). The 
relative configuration of the chiral reaction products was deduced by the comparsion of the 
experimentally observed ECD spectra to that obtained theorectically. 
 




Introduction    
 
One major goal for synthetic chemists is to create functionalised optically active molecules from 
readily available starting materials via stereoselective transformations, especially those which 
cannot be directly attained using biosynthetic pathways or natural products.1,2  In particular, 
optically active amino acids and their derivatives play a vital role in the design of crucial 
building blocks required to form peptide and proteins from the twenty naturally occurring 
proteinogenic L-amino acids. Moreover, non-proteinogenic unnatural amino acids have 
increasingly become valuable target molecules for drug discovery with expanding synthetic 
strategies over the last decade.3-9  These essential unnatural amino acids includes β-amino acids 
(β3 and β2), homo-amino acids, proline and pyruvic acid derivatives 
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 Unnatural proline based amino acids are used as important building blocks for 
pharmaceuticals, biologically active compounds and more recently as organocatalysts.10,11  
Proline is the only amino acid to exhibit helix-inducing properties (as a result of tertiary amide 
bond formation) when incorporated into a peptide thereby influencing its ligand binding and 
overall protein activity. Chiral polysubstituted oxopyrrolidine is one example exploited in this 
regard based on the proline backbone in order to synthesise unnatural proline based amino acid 
derivatives.12  
     As a result of modification at the α-position, these molecules display unique helix-inducing 
potential when incorporated into peptides.  This helix property promotes the restriction of 
conformational freedom amongst the amino acid side chains within the peptide structure which 
allows for resistance towards chemical and enzymatic degradation, increased hydrophobicity and 
metabolic stability.2,4 
     β-Amino acids are another class of compounds that are equally important precursors leading 
to more complex products with biological and pharmacological activities.13,14  Moreover β-amino 
acids are precursors of β-lactams, the most important class of antibiotics. They are known to also 
control the conformational properties of peptides based on β-amino acids that enhance the 
stability towards proteases.14  This contributes to the library of a drug development tool with 
degradation resistance.15  
     In the past decade, reports and reviews have been published on this topic, highlighting the 
possible strategies toward asymmetric synthesis of different kinds of substituted oxopyrrolidines 
in the optically active form.5,16   
     Asymmetric organocatalysed Mannich reactions emerged as a powerful strategy in the 
construction of these building blocks via the formation of quaternary α-amino acids.2,4,5,12  Some 
success has also been seen in direct addition of α-substituted amino acids to imines to afford 
these special kind of β-amino acid derivatives.3,17-19  The success of the reaction is highly 
dependent on the activation of both the nucleophile and electrophile.  Non-covalent interactions 
such as hydrogen bonding between the organocatalysts and substrates have been successfully 
exploited in asymmetric catalysis and in the synthesis of β-amino acid derivatives.20-22 
     Specifically, the use of urea- and thiourea-based organic molecules as hydrogen-bond-donor 
organocatalysts has been reported to be compatible with various substrates and reaction 
conditions.23-25  Jacobsen and co-workers developed a collection of thiourea catalysts that 
promote a diverse range of reactions with excellent enantioselectivity, along with the chiral 
versions as efficient hydrogen-bond-donor organocatalysts.26  Other groups such as; Jørgensen 
and Ricci and later Dixon, Takemoto, and Deng have all reported highly enantioselective 
Mannich reactions of β-ketoesters, catalysed by bifunctional cinchona alkaloid- derived 
organocatalysts.1,27  These catalysts are regarded as bifunctional chiral catalysts, bearing a 
tertiary amino group and hydrogen bond donors, which are expected to possess dual activation of 
both the electrophilic and nucleophilic components.25,28,29   
     In this study, we explore the ability of a urea-type cinchonine and quinine alkaloid derivatives 
to catalyse the Mannich reaction between the scarcely used N-Boc protected 3-ketoproline 
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Results and Discussion    
 
Several publications on the organocatalysed Mannich reactions of β-ketoesters with a range of 
aldimines have been reported to be successful, specifically those catalysed by bifunctional 
alkaloid-based urea possessing hydrogen bonding capability.30  Based on our previous studies on 
the 3-ketoproline core for the organocatalysed Michael reaction,31 we started by applying these 
optimised conditions for Mannich reactions of N-Boc protected 3-ketoproline (1) with N-Boc-
benzaldimine (2).  The reactions were performed at 20 °C with 20 mol % of catalyst, cinchonine 
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Scheme 1: Organocatalytic asymmetric Mannich reaction on N-Boc protected 3-ketoproline with 
N-Boc-aldimines 
 
     Catalyst I provided the product 3a in moderate isolated yield (65%), with a 70% ee and >99:1  
diastereoselectivity (dr).  For catalyst II, the product 3a was also isolated in moderate yield 
(68%) and enantioselectivity (73% ee) with equally high dr of >99:1.  Employing either of these 
catalysts in various solvents such as DCM, THF or ACN, toluene still provided the highest 
observed selectivity of 73% ee with up to 68% yield (see Table 1 SI). 
      With the optimised solvent, we then expanded the scope of the Mannich reaction (Figure 1) 
using both alkaloid-derived urea catalysts with a range of para-substituted aromatic and 
heteroaromatic aldimines (2a-p), including the electron donating and electron withdrawing 
heteroatoms.   
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Figure 1. Unnatural proline based amino acids derivatives obtained by the Mannich reaction of 
3-keto proline in the presence of catalysts I or II. All products were obtained with dr >99:1 from 
crude 1H NMR. 
 
     The products (3) were efficiently isolated (up to 80% yield and 97% ee) and (up to 68% yield 
and 95% ee) for cinchonine and quinine derived urea catalysts, respectively with a dr >99:1 
(Figure 1). As expected, when changing from catalyst I to II, the opposite enantiomer was 
obtained in all cases.  It was noted that electron withdrawing substituents at the para position had 
a positive effect on the yields and stereoselectivities.  Change of the protecting group on the 
imine component was also tolerated (3h) depicting the modular nature of the product adducts. 
Regrettably, many substrates (see Table 2 SI) showed very low reactivity, irrespective of the 
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catalyst used, which led to difficulties with purification.  The low reactivity was a likely result of 
electron donating substituents increasing the nucleophilicity of the substrates thus deactivating it 
towards nucleophilic attack.  The results obtained by either catalyst  revealed that the absence of 
the methoxy group in catalyst I generally promoted better yields and selectivities. This 
observation was similar to previous reports for other organocatalysed reactions on β-
ketoesters.32,33 This transformation provides a new and facile route in the formation of a new 
quaternary stereogenic center towards chiral α,α-disubstituted α-amino acids that are usually 
challenging to obtain, however desirable due to the useful properties.  
     In order to determine the relative absolute configuration of the reaction products, the 
electronic circular dichroism (ECD) was calculated for the four possible diastereoisomers of 3a 
as the model using time-dependent density functional theory (TDDFT) to simulate the 
experimentally observed ECD spectrum.34 The structures of the possible diastereoisomers were 
fixed at (S,R), (R,S), (S,S) and (R,R) absolute configurations and then optimized. Since the 
experimental measurements were carried out in methanol, the self-consistent reaction field 
(SCRF) with polarizable continuum model (PCM) was used for the solution state ECD spectra in 
methanol.35A comparison of the experimentally measured (3a, 3c) and computed ECD spectra 
showed that the overall patterns of the solution state ECD spectrum were consistent with those of 
the experimental. Thus products 3a (70% ee), and 3c (97% ee) could be assigned to the (S,S) 
relative absolute configuration. The stereochemistry of the remaining products was assigned by 
analogy. It has been stated that the definition of ECD is quite clear-cut however the simulation of 
an ECD spectrum has not yet being clearly documented.36 Nonetheless, this technique of 
determining the relative configuration of asymmetric adducts is slowly gaining popularity and 
will soon be a tool that is regularly used for the assignment of chirality. Please see computational 
details in the supporting information for the ECD spectra and an in depth discussion on the ECD 
calculations.35  Based on the high degree of diastereoselection and stereochemical outcome, the 
following transition state was proposed in which the catalyst deprotonates the β-ketoester as well 




Figure 2. Proposed transition state. 
 
General Papers  ARKIVOC 2016 (iii) 134-144 
 Page 139 ©ARKAT-USA, Inc. 
Conclusions    
 
We have developed an efficient method for the synthesis of a range of enantioenriched unnatural 
proline based amino acids.  Diastereoselective Mannich reactions of N-Boc protected 3-
ketoproline with a series of N-Boc-aldimines were achieved in good yields and 
enantioselectivities. Novel chiral unnatural proline based amino acids represent highly valuable 
building blocks for use in biomedical research, peptide/protein design and catalysis.  
   
  
Experimental Section     
 
General. Reagents and solvents were purchased from Aldrich, Merck and Fluka.  All NMR 
spectra were recorded on the Bruker AVANCE III 400 MHz or 600 MHz instruments at room 
temperature.  Chemical shifts are expressed in ppm and coupling constants are reported in Hz.  
Thin layer chromatography (TLC) was performed using Merck Kieselgel 60 F254. Crude 
compounds were purified with column chromatography using silica gel (60–200 mesh unless 
otherwise stated).  All solvents were dried using standard procedures. Optical rotations were 
recorded on a Bellingham + Stanley Polarimeter (Model 440+). High-resolution mass 
spectrometric data were obtained using a Bruker micrOTOF-Q II instrument operating at 
ambient temperatures and a sample concentration of approximately 1.0 ppm. For HPLC analysis: 
Agilent 1100 HPLC equipped with a ChiralPak IA/IB column 
 
Representative procedure for the Mannich reaction. A mixture of compound 1 (1.0 eq) and 
N-Boc-aldimines (1.2 eq) was stirred in the presence of the catalyst (0.20 eq) at 20°C.  The 
reaction progress was monitored using TLC. On completion of the reaction, the solvent was 
removed under reduced pressure and the crude product mixture was purified by column 
chromatography. 
1-tert-Butyl 2-ethyl 2-((tert-butoxycarbonylamino)(phenyl)methyl)-3-oxopyrrolidine-1,2-
dicarboxylate (3a). The crude material was purified by column chromatography (ethyl 
acetate/hexane, 15:85, Rf = 0.3) to afford the product (65%) as a yellowish oil. [α]23D = +0.20 (c 
= 0.01 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ 7.22-7.17 (m, 3H), 7.11-7.04 (m, 2H), 6.63-
6.26 (m, 1H), 5.74-5.56 (m, 1H) , 4.30-4.03 (m, 2H); 3.92-3.69 (m, 1H), 3.62-3.44 (m, 1H), 
2.64-2.58 (m, 1H), 2.54-2.45 (m, 1H),  1.49-1.33 (m, 18H), 1.22-1.16 (m, 3H);  13C NMR (100 
MHz, CDCl3): δ 166.1 (CO), 154.9 (CO), 153.1 (CO), 138.7 (C), 128.5 (2CH), 128.0 (CH), 
127.3 (2CH), 79.5 (2C) 61.9(CH2), 55.6 (CH), 41.3 (CH2), 36.3 (CH2), 28.3 (6CH3), 14.0 (CH3); 
HRMS (ESI+) m/z calcd. for C24H35N2O7: 463.2439; found [M+H] 463.2446; The enantiomeric 
excess was determined by HPLC with a Chiralpak IA-H column (hexane/2-PrOH = 97/3, 220 
nm, 0.7 mL/min); tmajor = 11.18 min, tminor = 13.36 min, 70% ee. 
1-tert-Butyl 2-ethyl 2-((tert-butoxycarbonylamino)(4-nitrophenyl)methyl)-3oxopyrrolidine -
1,2-dicarboxylate (3b). The crude material was purified by column chromatography (ethyl 
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acetate/hexane, 15:85, Rf = 0.3) to afford the product (60%) as a yellowish oil. [α]23D = +0.04 (c 
= 0.01 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ 8.28-8.06 (m, 2H), 7.52-7.31 (m, 2H), 6.61-
6.41 (m, 1H), 5.92-5.77 (m, 1H) , 4.38-4.17 (m, 2H), 4.14-4.09 (m, 2H), 3.74-3.52 (m, 1H), 2.70-
2.54 (m, 1H), 1.59-1.36 (m, 18H), 1.27-1.22 (m, 3H); 13C NMR (100 MHz, CDCl3): δ 210.5 
(CO), 166.2 (CO), 155.1 (CO), 153.0 (CO),148.7 (C), 147.9 (C), 124.6(2CH),123.6 (2CH), 80.1 
(2C), 62.8 (CH2), 56.3 (CH) 48.1 (CH2), 32.0 (CH2), 28.4 (6CH3), 13.9 (CH3); HRMS (ESI+) 
m/z calcd. For C24H34N3O9: 508.2290; found [M+H] 508.2292; The enantiomeric excess was 
determined by HPLC with a Chiralpak IA-H column (hexane/2-PrOH = 97/3, 254 nm, 0.7 
mL/min); tmajor = 22.65 min, tminor = 25.61 min, 79% ee. 
1-tert-Butyl 2-ethyl 2-((tert-butoxycarbonylamino)(4-(trifluoromethyl)phenyl)methyl)-3-
oxopyrrolidine-1,2-dicarboxylate (3c). The crude material was purified by column 
chromatography (ethyl acetate/hexane, 15:85, Rf = 0.5) to afford the product (56%) as a 
yellowish oil. [α]23D = +0.28 (c = 0.01 in CH2Cl2).  1H NMR (400 MHz, CDCl3): δ 7.55-7.51 
(m, 2H), 7.29-7.25 (m, 2H), 6.47-6.42 (m, 1H), 5.85-5.78 (m, 1H) , 4.28-4.16 (m, 2H), 3.73-3.69 
(m, 2H), 2.68-2.46 (m, 2H), 1.59-1.32 (m, 18H), 1.29-1.21 (m, 3H); 13C NMR (100 MHz, 
CDCl3): δ 174.6 (CO), 163.2 (CO), 154.9 (CO), 151.2 (CO), 129.8 (C), 127.9 (2CH), 125.4 
(2CH), 123.1 (CF), 105 (CH), 85 (2C), 62.4 (CH2), 55.3 (CH), 38.7 (CH2), 32.1 (CH2), 28.4 (6 
CH3), 14.1 (CH3); HRMS (ESI+) m/z calcd. For C24H34F3N2O7: 531.2313; found [M+H] 
531.2316; The enantiomeric excess was determined by HPLC with a Chiralpak IA-H column 
(hexane/2-PrOH = 97/3, 254 nm, 0.7 mL/min); tmajor = 8.07 min, tminor = 10.40 min, 97% ee. 
1-tert-Butyl 2-ethyl 2-((tert-butoxycarbonylamino)(4-chlorophenyl)methyl)-3-oxo-
pyrrolidine-1,2-dicarboxylate (3d). The crude material was purified by column 
chromatography (ethyl acetate/hexane, 15:85, Rf = 0.4) to afford the product (80%) as a 
yellowish oil. [α]23D = +0.24 (c = 0.01 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ 7.22-7.14 (m, 
2H), 7.06-7.00 (m, 2H), 6.34-6.27 (m, 1H), 5.72-5.60 (m, 1H) , 4.34-4.03 (m, 2H), 3.95-3.48 (m, 
1H), 3.62-3.44 (m, 1H), 2.63-2.42 (m, 2H), 1.65-1.27 (m, 18H), 1.20-1.15 (m, 3H); 13C NMR 
(100 MHz, CDCl3): δ 205.0 (CO), 166.2 (CO), 155.2 (CO), 153.2 (CO), 137.5 (C), 133.7 (C), 
128.7 (2CH), 128.4 (2CH), 104.2 (C), 79.6 (2C),  62.3 (CH2), 55.2 (CH) 41.7 (CH2), 36.5 (CH2), 
28.5 (6CH3), 14.0 (CH3) HRMS (ESI+) m/z calcd. for C24H34ClN2O7: 497.2049 [M+H] 
497.2050; The enantiomeric excess was determined by HPLC with a Chiralpak IA-H column 
(hexane/2-PrOH = 97/3, 254 nm, 0.7 mL/min); tmajor = 12.70 min, tminor = 14.83 min, 61% ee 
1-tert-Butyl 2-ethyl 2-((tert-butoxycarbonylamino)(furan-2-yl)methyl)-3-oxopyrrolidine-
1,2-dicarboxylate (3e). The crude material was purified by column chromatography (ethyl 
acetate/hexane, 15:85, Rf = 0.3) to afford the product (52%) as a yellowish oil. [α]23D =  -0.040 
(c = 0.01 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ 7.30-7.28 (m, 1H), 6.32-6.30 (m, 1H), 
6.23-6.05 (m, 2H), 5.90-5.85 (m, 1H), 4.31-4.12 (m, 2H) , 3.82-3.70 (m, 1H), 2.91-2.83 (m, 1H), 
2.77-2.72 (m, 1H), 2.58-2.49 (m, 1H), 1.59-1.43 (m, 18H), 1.30-1.25 (m, 3H); 13C NMR (100 
MHz, CDCl3): δ 209.9 (CO), 166.5 (CO), 154.9 (CO), 153.0 (CO), 151.2 (C), 142.2 (CH), 113.2 
(CH), 110.9 (CH), 108.3 (CH) 79.6 (2C), 62.5 (CH2), 50.4 (CH), 47.8 (CH2), 36.4 (CH2), 28.7 
(6CH3), 14.2 (CH3); HRMS (ESI+) m/z calcd. For C22H33N2O8: 453.2231; found [M+H] 
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453.2252; The enantiomeric excess was determined by HPLC with a Chiralpak IA-H column 
(hexane/2-PrOH = 97/3, 254 nm, 0.7 mL/min); tmajor = 14.91 min, tminor = 15.87 min, 95% ee 
1-tert-Butyl 2-ethyl 2-((tert-butoxycarbonylamino)(4-fluorophenyl)methyl)-3-
oxopyrrolidine-1,2-dicarboxylate (3f). The crude material was purified by column 
chromatography (ethyl acetate/hexane, 15:85, Rf = 0.4) to afford the product (68%) as a 
yellowish oil. [α]23D = +0.040 (c = 0.01 in CH2Cl2).  1H NMR (400 MHz, CDCl3): δ 7.22-7.14 
(m, 2H), 7.06-7.00 (m, 2H), 6.34-6.27 (m, 1H), 5.72-5.60 (m, 1H) , 4.34-4.09 (m, 2H), 4.03-3.48 
(m, 2H), 2.63-2.42 (m, 2H), 1.46-1.32 (m, 18H), 1.27-1.18 (m, 3H); 13C NMR (100 MHz, 
CDCl3): δ 208 (CO), 166 (CO), 163 (C), 155 (CO), 153 (CO), 134 (C),  129 (2CH), 115 (2CH), 
105 (CH), 79.6 (2C), 62.3 (CH2), 55 (CH), 41.7 (CH2), 36.5 (CH2), 28.3 (6CH3), 14.0 (CH3); 
HRMS (ESI+) m/z calcd. For C24H34FN2O7: 481.2345; found [M+H] 481.2343; The 
enantiomeric excess was determined by HPLC with a Chiralpak IA-H column (hexane/2-PrOH = 
93/7, 254 nm, 0.7 mL/min); tmajor = 13.98 min, tminor = 15.79 min, 7.5% ee. 
1-tert-Butyl 2-ethyl 2-(benzofuran-2-yl(tert-butoxycarbonylamino)methyl)-3-oxopyrrol-
idine-1,2-dicarboxylate ( 3g). The crude material was purified by column chromatography 
(ethyl acetate/hexane, 15:85, Rf = 0.4) to afford the product (72%) as a yellowish oil. [α]23D = 
+0.040 (c = 0.01 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ 7.51-7.49 (m, 1H), 7.39-7.33 (m, 
1H), 7.25-7.19 (m, 2H), 6.66-6.58 (m, 1H) , 6.25-6.15 (m, 1H), 6.10-6.00 (m, 1H), 4.28-4.08 (m, 
2H), 2.93-2.88 (m, 1H), 28.2-2.75 (m, 1H), 2.66-2.60 (m, 1H); 2.18-2.07 (m, 1H), 1.60-1.32 (m, 
18H), 1.29-1.23 (m, 3H); 13C NMR (100 MHz, CDCl3): δ 209.7 (CO),166.4 (CO), 156.8 (C), 
154.8 (CO), 154.1 (C), 153.2 (C), 152.2 (CO), 128.1 (C), 124.6 (CH), 123.8 (CH), 121.4 (CH), 
105.4 (CH), 103.6 (CH), 79.8 (2C), 62.4 (CH2), 50.9 (CH), 41.4 (CH2), 35.9 (CH2), 28.4 (3CH3), 
14.4 (CH3); HRMS (ESI+) m/z calcd. For C26H35N2O8: 503.2388; found [M+H] 503.2387; The 
enantiomeric excess was determined by HPLC with a Chiralpak IA-H column (hexane/2-PrOH = 
97/3, 254 nm, 0.7 mL/min); tmajor = 13.57 min, tminor = 15.34 min, 91% ee. 
1-tert-Butyl 2-ethyl 2-((benzyloxycarbonylamino)(phenyl)methyl)-3-oxopyrrolidine-1,2-
dicarboxylate (3h). The crude material was purified by column chromatography (ethyl 
acetate/hexane, 15:85, Rf = 0.3) to afford the product (69%) as a yellowish oil. [α]23D = +0.12 (c 
= 0.01 in CH2Cl2). 1H NMR (400 MHz, CDCl3): δ 7.27-7.7.26 (m, 2H), 7.24-7.14 (m, 6H), 6.64-
6.61 (m, 2H), 5.79-5.67 (m, 1H) , 5.0 (m, 2H), 4.20-4.0 (m, 2H), 2.53-2.46 (m, 1H), 2.32-2.26 
(m, 1H), 2.19-2.12 (m, 2H); 1.51-1.44 (m, 9H), 1.30-1.25 (m, 3H), 13C NMR (100 MHz, CDCl3): 
δ 211 (CO), 166 (CO), 155 (CO), 153 (CO), 138 (C), 138 (C), 128.6 (4 CH), 128.1 (2CH), 127 
(4CH), 82.6 (2C), 67.0 (CH2), 62.3 (CH2), 56.2 (CH), 41.4 (CH2), 36.5 (CH2), 28.3 (3CH3), 14.0 
(CH3); HRMS (ESI+) m/z calcd. For C27H33N2O7: 497.2282; found [M+H] 497.2270; The 
enantiomeric excess was determined by HPLC with a Chiralpak IA-H column (hexane/2-PrOH = 
97/3, 254 nm, 0.7 mL/min); tmajor = 30.72 min, tminor = 32.39, 89% ee. 
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